Where the Science Is Strongest and the Marketing Is Loudest
Epilepsy is the one domain of cannabis medicine where the evidence achieved the highest standard the modern system offers: an FDA approval. Epidiolex, a purified oral CBD, won approval in 2018 for two catastrophic pediatric epilepsy syndromes, Dravet syndrome and Lennox-Gastaut syndrome, on the strength of randomized controlled trials showing dramatic seizure reductions in populations whose seizures had defied every available medication. The approval was genuinely historic, the first cannabis-derived medicine in the modern era and the validation of a patient-parent movement that had spent years forcing the research establishment to pay attention. And yet the approval's content is persistently misunderstood, both by prohibitionists who treat it as proof that medical cannabis is a settled question and by advocates who treat it as proof that the whole plant is medicine. This post is the epilepsy evidence, honestly mapped: what the trials established, what the pipeline has produced since, and what patients and families navigating this landscape need to know.
What the Trials Established
The pivotal trials, run across multiple international sites, randomized children and young adults with Dravet or Lennox-Gastaut, both treatment-resistant syndromes with high mortality and profound disability, to Epidiolex or placebo added to their existing (extensive) medication regimens. The results were strong: median seizure reductions of roughly 40 to 50 percent on Epidiolex against far smaller reductions on placebo, with a meaningful fraction of patients achieving near-seizure-freedom at the titrated doses. For conditions where families had watched dozens of medications fail, the effect was transformative, and the anecdotal reports of dramatic responders, children going from hundreds of monthly seizures to a handful, were consistent with the trial averages rather than being promotional outliers.
Two design features deserve emphasis for honest interpretation. The trials studied purified CBD at pharmaceutical doses (hundreds to over a thousand milligrams daily), not the plant and not the wellness-market doses. And the control conditions were the patients' optimized medication regimens, meaning CBD's effect was demonstrated as an add-on, the realistic clinical position, rather than as a monotherapy. Both features matter for translating the evidence to the messy real world of the unregulated CBD market, where doses are fractions of the studied range and the products are unstandardized.
The Safety and Interaction Picture
The Epidiolex trials produced one of the most important drug-interaction findings in the entire cannabis literature: the hepatic-enzyme picture that this series' CYP450 post covered in depth was mapped at pharmaceutical scale. CBD at studied doses raised levels of co-administered antiepileptic drugs, most significantly clobazam (whose active metabolite roughly tripled in some patients, producing the sedation that became the trials' most common adverse effect) and valproate (whose liver-toxicity interaction with CBD produced the transaminase elevations that required monitoring and some discontinuations). The trials established the monitoring protocol, the dose-titration schedule, and the enzyme-interaction management that real-world CBD use almost entirely bypasses. The practical translation for any epilepsy patient using CBD in any form: the interaction picture with antiepileptic drugs is established, consequential, and manageable only with therapeutic-drug monitoring that the wellness market's consumers rarely receive.
Beyond Dravet and Lennox-Gastaut
The pipeline since the approval has extended in several directions with varying evidence quality. Tuberous sclerosis complex, another genetic epilepsy syndrome, won an additional Epidiolex indication on positive trial data. The broader epilepsy population, the common adult focal epilepsies, has seen survey signals and small studies suggesting some patients benefit, but the controlled evidence is thin and the effect sizes modest when measured. The THC question is genuinely unsettled: THC has anticonvulsant properties in preclinical models, and some patient communities report whole-plant benefit exceeding CBD-only benefit, but THC also carries proconvulsant potential at some doses in some models, and the whole-plant evidence remains anecdotal. The synthetic-cannabinoid research line (including THC analogs) continues with mixed results. The honest summary: for two specific catastrophic syndromes, the evidence is excellent. For the broad epilepsy population, the evidence is preliminary, individualized, and best approached through the specialist-guided structured trial this series recommends everywhere.
The Parent Movement's Legacy
The history deserves its own paragraph, because it shaped everything that followed. The modern epilepsy-cannabis evidence exists substantially because of parents, particularly the Colorado families whose children with Dravet syndrome experienced dramatic improvements with CBD-rich cannabis extracts and who, in the absence of any research infrastructure willing to study an illegal compound, moved to states with legal access, documented outcomes, built the advocacy networks, and forced the question onto the national agenda. The "Charlotte's Web" story (a CBD-rich cultivar named for a child whose seizures responded) became the public face of the movement, and the political pressure it generated funded the trials, moved the scheduling barriers, and produced the approval. It is one of the great case studies in this series' recurring theme: patient-driven evidence generation, forced by the research economy's failure to serve populations too small or too politicized for commercial interest, preceding and then compelling the institutional science.
The Bottom Line
Epilepsy is cannabis medicine's proof of concept and its cautionary tale at once: the strongest evidence in the field, achieved for specific catastrophic syndromes at pharmaceutical doses through rigorous trials, sitting beside a vast unregulated market selling CBD at doses that cannot replicate the studied effects to patients who cannot access the approved drug because of cost and access barriers. For families in the catastrophic-syndrome world, the pathway is established and the monitoring is non-negotiable. For the broader epilepsy population, the structured-trial discipline, the specialist partnership, the interaction audit, and the modest expectations of this series' chronic-pain coverage apply with equal force. The science did its job for the smallest and sickest. The work of extending it to everyone else remains, as everywhere in this series, unfinished and urgent.
The Closing Word
Epilepsy closes with the same structure as the series' other patient-driven chapters: the science reached the smallest and sickest first, because their parents forced it to, and the broad population's evidence remains the work of the next decade. The enzyme-interaction findings, the monitoring protocols, the dose-titration schedules: these are the settlement that pharmaceutical-grade research delivers, and they are exactly what the unregulated market's consumers do without. The closing guidance writes itself: for the catastrophic syndromes, the pathway is established and the specialist is the gate; for everything else, the structured trial, the interaction audit, the honest monitoring, and the neurologist in the loop. The molecule earned its approval. The market has not earned its trust. The distance between those two sentences is where the patients live, and it is the distance this series exists to map.
